title: FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases.
abstract: FRMD6 is an Ezrin/Radixin/Moesin (ERM) family protein and a human homologue of Drosophila expanded (ex). Ex functions in parallel of Drosophila merlin at upstream of the Hippo signaling pathway that controls proliferation, apoptosis, tissue regeneration, and tumorigenesis. Even though the core kinase cascade (MST1/2-Lats1/2-YAP/TAZ) of the Hippo pathway has been well established, its upstream regulators are not well understood. Merlin promotes activation of the Hippo pathway. However, the effect of FRMD6 on the Hippo pathway is controversial. Little is known about how FRMD6 functions and the potential role of FRMD in gliomagenesis and glioblastoma (GBM) progression. We demonstrate for the first time that FRMD6 is down-regulated in human GBM cells and tissues and that increased FRMD6 expression inhibits whereas FRMD6 knockdown promotes GBM cell proliferation/invasion in vitro and GBM growth/progression in vivo. Furthermore, we demonstrate that unlike increased expression of merlin, which enhances the stress induced activation of the Hippo pathway, increased FRMD6 expression displays little effect on the pathway. In contrast, we show that FRMD6 inhibits activation of a couple of receptor tyrosine kinases (RTKs) including c-Met and PDGFR and their downstream Erk and AKT kinases. Moreover, we show that expression of constitutively active c-Met, the TPR-Met fusion protein, largely reverses the anti-GBM effect of FRMD6 in vivo, suggesting that FRMD6 functions at least partially through inhibiting activity of RTKs especially c-Met. These results establish a novel function of FRMD6 in inhibiting human GBM growth and progression and uncover a novel mechanism by which FRMD6 exerts its anti-GBM activity.
authors.affiliation: Department of Oncological Sciences Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
authors.forename: Yin
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Oncological Sciences Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
authors.forename: Kaiqiang
authors.initials: K
authors.lastname: Wang
authors.affiliation: Department of Oncological Sciences Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
authors.forename: Qin
authors.initials: Q
authors.lastname: Yu
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003598:Cytoskeletal Proteins / Q000502:physiology*; D005260:Female; D005909:Glioblastoma / Q000473:pathology*; D000090683:Hippo Signaling Pathway; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000502:physiology*; D051379:Mice; D009361:Neoplasm Invasiveness; D017346:Protein Serine-Threonine Kinases / Q000502:physiology; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D015398:Signal Transduction
chemical_list: D003598:Cytoskeletal Proteins; C504793:FRMD6 protein, human; D008565:Membrane Proteins; D019859:Proto-Oncogene Proteins c-met; D020794:Receptor Protein-Tyrosine Kinases; D017346:Protein Serine-Threonine Kinases
keywords: FRMD6; c-Met; glioblastoma; hippo signaling pathway; receptor tyrosine kinase